Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Autor:	O'Dwyer, Michael C, Kent, Emma *, Parker, Michael *, Swords, Ronan T. *, Giles, Frank, Coutre, Philipp le, Padmanabhan, Swaminathan, Moulton, Brian *, McMullin, Mary Frances *, Langabeer, Stephen *, Egan, Karine *, Conneally, Eibhlin
Zdroj:	In Blood 20 November 2009 114(22):3294-3294
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu